Q3 2024 revenue fell 22.8% YoY to ₩43.4B, with net income at ₩2.18B. Bio-Chemical led sales, while Bio-Medical posted losses. R&D investment remains high, and the company is expanding production capacity for nucleosides and mPEG amid strong biotech demand.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.